CompletedPhase 3

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

United States734 participantsStarted 2002-05

Plain-language summary

This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medications (metformin and a sulfonylurea) throughout the study.

Who can participate

Age range16 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects with Type 2 diabetes mellitus * Treated with both metformin and a sulfonylurea at defined doses for at least 3 months prior to screening * BMI= 27-45 kg/m2 * HbA1c value between 7.5% and 11% Exclusion Criteria: * Treated with oral anti-diabetic medications other than metformin and sulfonylurea within 3 months of screening * Patients treated previously with AC2993 * Patients presently treated with insulin

What they're measuring

Change in HbA1c from Baseline to Week 30

Timeframe: Baseline (Day 1) to Week 30

Trial details

NCT IDNCT00035984

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2003-08

View on ClinicalTrials.gov More Diabetes Mellitus, Non-Insulin-Dependent trials